Annual CFO
$49.58 M
-$88.27 M-64.04%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual cash flow from operations is currently $49.58 million, with the most recent change of -$88.27 million (-64.04%) on 31 December 2023. During the last 3 years, it has fallen by -$5.01 million (-9.18%). LGND annual CFO is now -74.45% below its all-time high of $194.06 million, reached on 31 December 2018.LGND Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$36.53 M
+$23.22 M+174.37%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly cash flow from operations is currently $36.53 million, with the most recent change of +$23.22 million (+174.37%) on 30 September 2024. Over the past year, it has increased by +$28.88 million (+377.77%). LGND quarterly CFO is now -50.40% below its all-time high of $73.64 million, reached on 30 June 2018.LGND Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$76.64 M
+$28.88 M+60.48%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM cash flow from operations is currently $76.64 million, with the most recent change of +$28.88 million (+60.48%) on 30 September 2024. Over the past year, it has dropped by -$18.34 million (-19.31%). LGND TTM CFO is now -60.51% below its all-time high of $194.06 million, reached on 31 December 2018.LGND TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.0% | +377.8% | -19.3% |
| 3 y3 years | -9.2% | +82.4% | +48.3% |
| 5 y5 years | -74.5% | +689.5% | +624.7% |
LGND Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -64.0% | at low | -31.7% | >+9999.0% | -44.4% | +123.0% |
| 5 y | 5 years | -74.5% | +269.0% | -31.7% | +597.8% | -44.4% | +232.9% |
| alltime | all time | -74.5% | +135.8% | -50.4% | +143.4% | -60.5% | +141.0% |
Ligand Pharmaceuticals Incorporated Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $36.53 M(+174.4%) | $76.64 M(+60.5%) |
| June 2024 | - | $13.31 M(-28.9%) | $47.76 M(+39.0%) |
| Mar 2024 | - | $18.73 M(+132.3%) | $34.36 M(-30.7%) |
| Dec 2023 | $49.58 M(-64.0%) | $8.06 M(+5.5%) | $49.58 M(-47.8%) |
| Sept 2023 | - | $7.65 M(-9424.4%) | $94.98 M(-11.9%) |
| June 2023 | - | -$82.00 K(-100.2%) | $107.83 M(-10.0%) |
| Mar 2023 | - | $33.95 M(-36.5%) | $119.79 M(-13.1%) |
| Dec 2022 | $137.85 M(+74.9%) | $53.47 M(+161.0%) | $137.85 M(+23.1%) |
| Sept 2022 | - | $20.49 M(+72.5%) | $112.02 M(+0.4%) |
| June 2022 | - | $11.88 M(-77.2%) | $111.56 M(-7.1%) |
| Mar 2022 | - | $52.01 M(+88.2%) | $120.06 M(+52.4%) |
| Dec 2021 | $78.80 M(+44.4%) | $27.64 M(+38.0%) | $78.80 M(+52.4%) |
| Sept 2021 | - | $20.02 M(-1.7%) | $51.69 M(+16.4%) |
| June 2021 | - | $20.38 M(+89.5%) | $44.41 M(-8.3%) |
| Mar 2021 | - | $10.75 M(+1902.6%) | $48.42 M(-11.3%) |
| Dec 2020 | $54.59 M(-286.1%) | $537.00 K(-95.8%) | $54.59 M(+16.9%) |
| Sept 2020 | - | $12.74 M(-47.7%) | $46.71 M(+68.2%) |
| June 2020 | - | $24.38 M(+44.1%) | $27.77 M(-148.1%) |
| Mar 2020 | - | $16.92 M(-330.6%) | -$57.67 M(+96.6%) |
| Dec 2019 | -$29.34 M(-115.1%) | -$7.34 M(+18.4%) | -$29.34 M(-377.4%) |
| Sept 2019 | - | -$6.20 M(-89.9%) | $10.57 M(-75.9%) |
| June 2019 | - | -$61.06 M(-234.9%) | $43.85 M(-75.4%) |
| Mar 2019 | - | $45.26 M(+38.9%) | $178.56 M(-8.0%) |
| Dec 2018 | $194.06 M(+119.1%) | $32.57 M(+20.3%) | $194.06 M(+0.7%) |
| Sept 2018 | - | $27.08 M(-63.2%) | $192.80 M(-0.3%) |
| June 2018 | - | $73.64 M(+21.2%) | $193.37 M(+48.6%) |
| Mar 2018 | - | $60.76 M(+94.1%) | $130.11 M(+46.9%) |
| Dec 2017 | $88.57 M(+45.8%) | $31.31 M(+13.2%) | $88.57 M(+16.6%) |
| Sept 2017 | - | $27.65 M(+166.2%) | $75.98 M(+13.7%) |
| June 2017 | - | $10.39 M(-46.0%) | $66.86 M(+0.0%) |
| Mar 2017 | - | $19.22 M(+2.7%) | $66.84 M(+10.1%) |
| Dec 2016 | $60.73 M(+45.5%) | $18.73 M(+1.1%) | $60.73 M(+9.1%) |
| Sept 2016 | - | $18.52 M(+78.6%) | $55.67 M(+17.0%) |
| June 2016 | - | $10.37 M(-20.9%) | $47.59 M(+0.7%) |
| Mar 2016 | - | $13.11 M(-4.0%) | $47.26 M(+13.3%) |
| Dec 2015 | $41.73 M(+102.9%) | $13.66 M(+30.9%) | $41.73 M(+8.9%) |
| Sept 2015 | - | $10.44 M(+3.9%) | $38.31 M(+21.2%) |
| June 2015 | - | $10.05 M(+32.6%) | $31.61 M(+23.6%) |
| Mar 2015 | - | $7.58 M(-26.0%) | $25.57 M(+24.3%) |
| Dec 2014 | $20.57 M(-0.6%) | $10.25 M(+174.3%) | $20.57 M(-8.0%) |
| Sept 2014 | - | $3.73 M(-6.8%) | $22.35 M(+22.4%) |
| June 2014 | - | $4.01 M(+55.5%) | $18.26 M(-13.8%) |
| Mar 2014 | - | $2.58 M(-78.6%) | $21.19 M(+2.4%) |
| Dec 2013 | $20.69 M(>+9900.0%) | $12.03 M(-3452.1%) | $20.69 M(+91.1%) |
| Sept 2013 | - | -$359.00 K(-105.2%) | $10.83 M(+5.4%) |
| June 2013 | - | $6.94 M(+233.8%) | $10.28 M(+294.1%) |
| Mar 2013 | - | $2.08 M(-4.3%) | $2.61 M(+1519.9%) |
| Dec 2012 | $161.00 K(-113.7%) | $2.17 M(-338.7%) | $161.00 K(-96.8%) |
| Sept 2012 | - | -$910.00 K(+24.3%) | $5.01 M(+3.0%) |
| June 2012 | - | -$732.00 K(+98.4%) | $4.86 M(-298.2%) |
| Mar 2012 | - | -$369.00 K(-105.3%) | -$2.45 M(+109.2%) |
| Dec 2011 | -$1.17 M(-95.7%) | $7.02 M(-765.1%) | -$1.17 M(-87.6%) |
| Sept 2011 | - | -$1.05 M(-86.9%) | -$9.49 M(-41.1%) |
| June 2011 | - | -$8.04 M(-983.1%) | -$16.11 M(+56.7%) |
| Mar 2011 | - | $911.00 K(-170.1%) | -$10.28 M(-62.0%) |
| Dec 2010 | -$27.07 M(-19.9%) | -$1.30 M(-83.1%) | -$27.07 M(+0.0%) |
| Sept 2010 | - | -$7.67 M(+246.1%) | -$27.06 M(-11.9%) |
| June 2010 | - | -$2.22 M(-86.0%) | -$30.72 M(+20.2%) |
| Mar 2010 | - | -$15.88 M(+1131.7%) | -$25.56 M(-24.4%) |
| Dec 2009 | -$33.80 M | -$1.29 M(-88.6%) | -$33.80 M(+28.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2009 | - | -$11.34 M(-484.4%) | -$26.32 M(-7.4%) |
| June 2009 | - | $2.95 M(-112.2%) | -$28.43 M(-19.6%) |
| Mar 2009 | - | -$24.12 M(-489.5%) | -$35.35 M(+71.4%) |
| Dec 2008 | -$20.63 M(-78.9%) | $6.19 M(-146.1%) | -$20.63 M(-42.1%) |
| Sept 2008 | - | -$13.45 M(+238.7%) | -$35.60 M(-2.2%) |
| June 2008 | - | -$3.97 M(-57.8%) | -$36.39 M(-41.1%) |
| Mar 2008 | - | -$9.40 M(+7.0%) | -$61.78 M(-36.8%) |
| Dec 2007 | -$97.73 M(-29.4%) | -$8.79 M(-38.3%) | -$97.73 M(-43.5%) |
| Sept 2007 | - | -$14.23 M(-51.5%) | -$173.01 M(-7.4%) |
| June 2007 | - | -$29.36 M(-35.3%) | -$186.80 M(+14.0%) |
| Mar 2007 | - | -$45.35 M(-46.1%) | -$163.89 M(+18.3%) |
| Dec 2006 | -$138.52 M(-1756.0%) | -$84.07 M(+200.0%) | -$138.52 M(+226.9%) |
| Sept 2006 | - | -$28.02 M(+334.6%) | -$42.38 M(+460.3%) |
| June 2006 | - | -$6.45 M(-67.7%) | -$7.56 M(-16.2%) |
| Mar 2006 | - | -$19.98 M(-265.5%) | -$9.02 M(-207.9%) |
| Dec 2005 | $8.37 M(+45.4%) | $12.07 M(+77.7%) | $8.37 M(-67.2%) |
| Sept 2005 | - | $6.79 M(-186.0%) | $25.46 M(+118.9%) |
| June 2005 | - | -$7.91 M(+204.4%) | $11.63 M(+47.4%) |
| Mar 2005 | - | -$2.60 M(-108.9%) | $7.89 M(+37.1%) |
| Dec 2004 | $5.75 M(+1738.3%) | $29.17 M(-514.4%) | $5.75 M(-140.5%) |
| Sept 2004 | - | -$7.04 M(-39.6%) | -$14.20 M(+45.3%) |
| June 2004 | - | -$11.65 M(+146.1%) | -$9.78 M(-283.5%) |
| Mar 2004 | - | -$4.73 M(-151.4%) | $5.33 M(+1601.9%) |
| Dec 2003 | $313.00 K(-101.2%) | $9.21 M(-452.9%) | $313.00 K(-101.5%) |
| Sept 2003 | - | -$2.61 M(-175.5%) | -$20.24 M(-4.3%) |
| June 2003 | - | $3.46 M(-135.5%) | -$21.16 M(-42.0%) |
| Mar 2003 | - | -$9.75 M(-14.0%) | -$36.50 M(+35.7%) |
| Dec 2002 | -$26.89 M(+35.1%) | -$11.34 M(+221.6%) | -$26.89 M(+41.4%) |
| Sept 2002 | - | -$3.53 M(-70.3%) | -$19.02 M(-15.3%) |
| June 2002 | - | -$11.88 M(+8327.7%) | -$22.45 M(+225.1%) |
| Mar 2002 | - | -$141.00 K(-95.9%) | -$6.91 M(-65.3%) |
| Dec 2001 | -$19.91 M(-56.0%) | -$3.47 M(-50.1%) | -$19.91 M(-20.0%) |
| Sept 2001 | - | -$6.96 M(-289.9%) | -$24.89 M(-22.4%) |
| June 2001 | - | $3.66 M(-127.9%) | -$32.07 M(-27.9%) |
| Mar 2001 | - | -$13.14 M(+55.5%) | -$44.49 M(-1.6%) |
| Dec 2000 | -$45.22 M(-24.3%) | -$8.45 M(-40.3%) | -$45.22 M(-2.1%) |
| Sept 2000 | - | -$14.14 M(+61.5%) | -$46.16 M(-0.3%) |
| June 2000 | - | -$8.76 M(-36.8%) | -$46.32 M(-10.2%) |
| Mar 2000 | - | -$13.86 M(+47.5%) | -$51.56 M(-13.6%) |
| Dec 1999 | -$59.70 M(-10.4%) | -$9.40 M(-34.3%) | -$59.70 M(-10.6%) |
| Sept 1999 | - | -$14.30 M(+2.1%) | -$66.80 M(-5.6%) |
| June 1999 | - | -$14.00 M(-36.4%) | -$70.80 M(+3.4%) |
| Mar 1999 | - | -$22.00 M(+33.3%) | -$68.50 M(+2.9%) |
| Dec 1998 | -$66.60 M(+397.0%) | -$16.50 M(-9.8%) | -$66.60 M(+79.5%) |
| Sept 1998 | - | -$18.30 M(+56.4%) | -$37.10 M(+27.9%) |
| June 1998 | - | -$11.70 M(-41.8%) | -$29.00 M(+14.6%) |
| Mar 1998 | - | -$20.10 M(-254.6%) | -$25.30 M(+88.8%) |
| Dec 1997 | -$13.40 M(-59.8%) | $13.00 M(-227.5%) | -$13.40 M(-59.0%) |
| Sept 1997 | - | -$10.20 M(+27.5%) | -$32.70 M(+0.6%) |
| June 1997 | - | -$8.00 M(-2.4%) | -$32.50 M(-2.4%) |
| Mar 1997 | - | -$8.20 M(+30.2%) | -$33.30 M(0.0%) |
| Dec 1996 | -$33.30 M(-12.1%) | -$6.30 M(-37.0%) | -$33.30 M(+23.3%) |
| Sept 1996 | - | -$10.00 M(+13.6%) | -$27.00 M(+58.8%) |
| June 1996 | - | -$8.80 M(+7.3%) | -$17.00 M(+107.3%) |
| Mar 1996 | - | -$8.20 M(+182.8%) | -$8.20 M(-43.1%) |
| Dec 1995 | -$37.90 M(+165.0%) | - | - |
| Mar 1995 | - | -$2.90 M(-31.0%) | -$14.40 M(+0.7%) |
| Dec 1994 | -$14.30 M | -$4.20 M(+40.0%) | -$14.30 M(+41.6%) |
| Sept 1994 | - | -$3.00 M(-30.2%) | -$10.10 M(+42.3%) |
| June 1994 | - | -$4.30 M(+53.6%) | -$7.10 M(+153.6%) |
| Mar 1994 | - | -$2.80 M | -$2.80 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual cash flow from operations?
- What is the all time high annual CFO for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual CFO year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly cash flow from operations?
- What is the all time high quarterly CFO for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly CFO year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM cash flow from operations?
- What is the all time high TTM CFO for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM CFO year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual cash flow from operations?
The current annual CFO of LGND is $49.58 M
What is the all time high annual CFO for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual cash flow from operations is $194.06 M
What is Ligand Pharmaceuticals Incorporated annual CFO year-on-year change?
Over the past year, LGND annual cash flow from operations has changed by -$88.27 M (-64.04%)
What is Ligand Pharmaceuticals Incorporated quarterly cash flow from operations?
The current quarterly CFO of LGND is $36.53 M
What is the all time high quarterly CFO for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly cash flow from operations is $73.64 M
What is Ligand Pharmaceuticals Incorporated quarterly CFO year-on-year change?
Over the past year, LGND quarterly cash flow from operations has changed by +$28.88 M (+377.77%)
What is Ligand Pharmaceuticals Incorporated TTM cash flow from operations?
The current TTM CFO of LGND is $76.64 M
What is the all time high TTM CFO for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM cash flow from operations is $194.06 M
What is Ligand Pharmaceuticals Incorporated TTM CFO year-on-year change?
Over the past year, LGND TTM cash flow from operations has changed by -$18.34 M (-19.31%)